The carboxyl terminus of type VII collagen mediates antiparallel dimer formation and constitutes a new antigenic epitope for epidermolysis Bullosa acquisita autoantibodies.
Type VII collagen, the major component of anchoring fibrils, consists of a central collagenous triple-helical domain flanked by two noncollagenous domains, NC1 and NC2. The NC2 domain has been implicated in catalyzing the antiparallel dimer formation of type VII procollagen. In this study, we produced the entire 161 amino acids of the NC2 domain plus 186 amino acids of adjacent collagenous domain (NC2/COL) and purified large quantities of the recombinant NC2/COL protein. Recombinant NC2/COL readily formed disulfide-bonded hexamers, each representing one antiparallel dimer of collagen VII. Removal of the collagenous helical domain from NC2/COL by collagenase digestion abolished the antiparallel dimer formation. Using site-directed mutagenesis, we found that mutation of either cysteine 2802 or cysteine 2804 alone within the NC2 domain blocked antiparallel dimer formation. In contrast, a single cysteine mutation, 2634, within the collagenous helical domain had no effect. A generated methionine to lysine substitution, M2798K, that is associated with recessive dystrophic epidermolysis bullosa, was unable to form antiparallel dimers. Furthermore, autoantibodies from epidermolysis bullosa acquisita patients also reacted with NC2/COL. We conclude that NC2 and its adjacent collagenous segment mediate antiparallel dimer formation of collagen VII. Epidermolysis bullosa acquisita autoantibodies bound to this domain may destabilize anchoring fibrils by interfering with antiparallel dimer assembly leading to epidermal-dermal disadherence.
Chen
M
M
Department of Medicine, Division of Dermatology, University of Southern California, Los Angeles, California 90033, USA.
Keene
D R
DR
Costa
F K
FK
Tahk
S H
SH
Woodley
D T
DT
D019943:Amino Acid Substitution; D001323:Autoantibodies / Q000737:chemistry* / Q000276:immunology; D001666:Binding Sites, Antibody; D002460:Cell Line; D003094:Collagen / Q000737:chemistry* / Q000276:immunology* / Q000648:ultrastructure; D019281:Dimerization; D016107:Epidermolysis Bullosa Acquisita / Q000276:immunology*; D000939:Epitopes / Q000737:chemistry; D006801:Humans; D016297:Mutagenesis, Site-Directed; D010446:Peptide Fragments / Q000737:chemistry / Q000276:immunology / Q000648:ultrastructure; D011347:Procollagen / Q000737:chemistry / Q000276:immunology; D017433:Protein Structure, Secondary; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000276:immunology; D011994:Recombinant Proteins / Q000737:chemistry / Q000276:immunology / Q000648:ultrastructure; D014162:Transfection
D001323:Autoantibodies; D000939:Epitopes; D010446:Peptide Fragments; D011347:Procollagen; D011993:Recombinant Fusion Proteins; D011994:Recombinant Proteins; D003094:Collagen